The NAD+ problem
Nicotinamide adenine dinucleotide (NAD+) is a coenzyme present in every living cell, essential for hundreds of metabolic reactions and for the function of sirtuins — proteins that govern DNA repair, gene expression, and mitochondrial biogenesis. NAD+ levels decline by roughly fifty percent between age twenty and age fifty in most tissues, and the consequences are measurable: impaired mitochondrial function, reduced DNA repair capacity, and a shift in cellular metabolism toward inflammation.
The therapeutic thesis is straightforward: restoring NAD+ to youthful levels should restore the enzymatic activity it supports. The question is how to get it into cells efficiently.
Precursors vs. direct infusion
Oral NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are the most-studied delivery vehicles. Multiple randomized controlled trials in humans confirm that oral NMN raises blood and muscle NAD+ levels measurably. The magnitude of cellular restoration at tissue level remains debated.
Direct IV NAD+ infusion bypasses the precursor conversion step and produces rapid, sustained plasma NAD+ elevation. Clinical reports of improved energy, cognitive clarity, and sleep quality are consistent. The evidence base is smaller than for oral precursors — but the mechanism is direct.
| Form | Route | Evidence level | Time to effect | Practical notes |
|---|---|---|---|---|
| NMN / NR | Oral | RCT data in humans | 2–4 weeks | Convenient; lower cost; moderate tissue delivery |
| IV NAD+ | Intravenous | Smaller trials + case series | Hours to days | Direct plasma elevation; infusion clinic required |
| SC NAD+ | Subcutaneous | Early clinical use | 1–3 days | Emerging; more convenient than IV; compounded only |
MOTS-c: mitochondria's own hormone
MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) is a peptide encoded in mitochondrial DNA itself — the first mitochondria-derived regulatory peptide identified in humans. It activates AMPK, the cellular energy sensor, and has been shown to improve insulin sensitivity in skeletal muscle with effects comparable to exercise in some animal models.
Human data is limited but compelling: MOTS-c levels are lower in older adults and in populations with metabolic disease. Exogenous MOTS-c supplementation in aging rodent models improved metabolic markers and extended healthspan. Clinical trials in humans are ongoing.
Measuring biological age — the Horvath clock and beyond
The clinical question is: how do you know if a longevity intervention is working? Chronological age is fixed. Biological age, as measured by epigenetic DNA methylation clocks (Horvath, GrimAge, PhenoAge), is not. Validated epigenetic clocks correlate with mortality risk, disease incidence, and physiological function — and they respond to interventions.
Nexphoria's longevity protocols are benchmarked at baseline and at one year using a validated biological age assessment. A protocol that doesn't move the needle on measurable markers is re-evaluated. Dare to defy. Find your focus. Measure the result.
Share
References